Moderna, Inc. (MRNA)
Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors who lost money on Moderna, Inc.(MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNA
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna and Coursera Launch Free Course on mRNA Technology
Companies share joint commitment to leveraging technology for STEM education Accessible education on cutting-edge science and technology represents critical step toward closing workforce readiness gap CAMBRIDGE, MA and MOUNTAIN VIEW, CA / ACCESSWIRE / August 14, 2024 / Moderna, Inc. (NASDAQ:MRNA) and Coursera (NYSE:COUR) today announced a partnership to launch mRNAs as Medicines , a three-module course designed by experts at Moderna that offers a comprehensive understanding of mRNA medicines, how they work and their potential applications. mRNAs as Medicines is available for free to individuals who register as Coursera learners.
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Inc Investors Can Take The Lead In Securities Fraud Lawsuit With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors Who Lost Money on Moderna, Inc. (MRNA) Should Contact Levi & Korsinsky About Pending Class Action - MRNA
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv- 12058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
3 Biotech Stocks Poised for a Comeback After Last Week's Market Meltdown
Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle.
